ProfoundBio

Executive Summary

ProfoundBio is a Seattle-based, clinical-stage biotechnology company pioneering next-generation antibody-drug conjugates (ADCs) for solid tumors. Its proprietary linker-payload platform aims to overcome limitations of traditional ADCs by enhancing therapeutic index and reducing off-target toxicity. The company's lead program, targeting a validated tumor-associated antigen, is currently in Phase 2 clinical development, with promising early efficacy and safety data. Supported by $112 million in total funding, ProfoundBio is well positioned to advance its pipeline and potentially address significant unmet needs in oncology. The company is privately held and has not disclosed a valuation.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 interim data readout for lead ADC program60% success
• Q3 2026Potential partnership or licensing deal for novel ADC platform45% success
• Q4 2026FDA clearance for IND of next-generation ADC candidate75% success